Recent Updates
Recently added Catalysts
PRLD Positive Sentiment

A Phase 1 Study of PRT3789, a Potent and Selective Degrader of SMARCA2 in Patients with Advanced or Metastatic Solid Tumors and a SMARCA4 Mutation

Monday, October 23, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses a Phase 1 study of PRT3789, a selective degrader targeting SMARCA2 in patients with advanced or metastatic solid tumors possessing a SMARCA4 mutation. The study aims to evaluate the safety and efficacy of this novel therapeutic approach. A team of notable researchers is involved in this clinical trial.
Price reaction · baseline $2.39 (2023-10-20 close) · hit pre-market · clean, no other PRLD news in the window
day 0 close
-10.5%
day 1
-11.7%
day 3 · peak
-16.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • The study focuses on a novel treatment for advanced solid tumors.
  • PRT3789 is designed to selectively target SMARCA2 mutations.
  • Involvement of a diverse group of experienced researchers.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+217%
120-day peak, hindsight
Typical move
8.2%
average across 4 past catalysts
Cash runway
~29 mo
Minimal dilution risk
Lead asset
PRT1419
Phase 1 · Multiple Myeloma

Full Press Release Details

Ibiayi Dagogo‐Jack, Afshin Dowlati, Robin Guo, Mark Awad, Aurelie Swalduz, Emiliano Calvo, Victor Moreno, Alex Adjei, Patricia LoRusso, Salman Punekar, Ticiana Leal, Timothy A. Yap, Antoine Italiano, William Novotny, Chris Tankersley, Sarah Rowe, Gina Paris, William Sun, Alex Spira, and Benjamin Besse

Frequently Asked Questions

What is PRT3789?

PRT3789 is a potent and selective degrader targeting SMARCA2.

What type of tumors is PRT3789 being studied for?

It is being studied for advanced or metastatic solid tumors.

Who is leading the Phase 1 study of PRT3789?

A team of experienced researchers is leading the study.

What mutation does PRT3789 target?

PRT3789 targets tumors with a SMARCA4 mutation.

ShareAdd on Google
Tags: PRLD Viatris Investor Conferences Healthcare PRT3789 SMARCA2 solid tumors clinical trial
Last updated: Oct 23, 2023

Biotech snapshot

Cash runway
$152M liquidity · $5M/mo burn
~29 mo
Minimal dilution risk
Lead asset
PRT1419Phase 1
Multiple Myeloma →

Catalyst track record

+217%
best trade around PRLD's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for PRLD.

See every catalyst's timing & PoA →